ezutromid discontinu downgrad perform
announc posit top-lin data infliximab biosimilar abp
potenti upsid outlook
posit interim result prompt revis regulatori strategi
analyst certif import disclosur see
ezutromid discontinu downgrad perform
morn summit open follow announc lead asset ezutromid meet primari secondari
endpoint final data phase phaseout dmd studi base disappoint result smmt discontinu
develop program refocus resourc infecti diseas pipelin posit potenti ridinilazol difficil
infect cdi believ major investor date ascrib littl valu smmt antibiot pipelin consid upsid
ezutromid near-term uncertainti lack materi catalyst ridinilazol phase initi data late
remov dmd revenu estim downgrad smmt perform outperform
announc posit top-lin data infliximab biosimilar abp potenti upsid outlook
estim biosimilar could account billion sale account nearli sale continu
believ one compani impact develop market biosimilar support develop
field l\past year highlight april report biosimilar updat suprem court uphold constitution
inter part review posit biosimilar brand drug octob report biosimilar updat potenti chang legal
landscap add uncertainti current includ biosimilar abp abp abp outlook base
top-lin data announc today abp could provid upsid biosimilar outlook
posit interim result prompt revis regulatori strategi voxelotor
global blood today report interim part result phase trial voxelotor sickl cell diseas scd result show
convinc dose-depend statist signific improv primari hemoglobin hb respons endpoint improv
symptom-bas endpoint less definit could reflect short durat follow-up incid vaso-occlus crise
voc trend toward improv treatment compani announc plan pursu bold regulatori strategi file acceler
approv base hb respons alon pend fda feedback believ combin robust hb respons trend voc benefit
de facto gold standard endpoint scd clean safeti profil suggest high likelihood fda approv reiter outperform pt
